nanoparticles

Figure
4 Standard calibration curve of the 5-FU Solution in between Concentration (µg/ml) vs
Absorbance (nm).

Abbreviations: 5-FU, 5-Fluorouracil.

pH 7.4

pH 4.5

Figure 5 In vitro
releases of ?-T-FU-PLGA-NPs and 5-FU-PLGA-NPs in PBS at pH 7.4 & 4.5.

Abbreviations:
?-T-FU-PLGA-NPs, targeted ?-Tocopherol-5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; 5-FU-PLGA-NPs non-targeted 5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; PBS, phosphate buffer saline.

(A)

(B)

Figure
6 Cytotoxicity study, Inhibition rate of
?-T-FU-PLGA-NPs and 5-FU-PLGA-NPs in SCC15 cells detected by MTT assay. (n=3;
mean ± standard deviation).

Notes: (A) Inhibition rate of different
dose-concentration-time (24, 48, 72 hours) of 5-FU-PLGA-NPs on SCC15 cells. (B) Inhibition rate of different
dose-concentration-time (24, 48, 72 hours) of ?-T-FU-PLGA-NPs on SCC15 cells.

Abbreviations:
?-T-FU-PLGA-NPs, targeted ?-Tocopherol-5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; 5-FU-PLGA-NPs, non-targeted 5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; SCC15, squamous cell carcinoma-15 cells; MTT, methyl thiazolyl
tetrazolium assay.

Figure
7 Cytotoxicity study, Inhibition rate of ?-T-FU-PLGA-NPs and
5-FU-PLGA-NPs on SCC15 cells up to time 160 hours.

Abbreviations:
?-T-FU-PLGA-NPs, targeted ?-Tocopherol-5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; 5-FU-PLGA-NPs, non-targeted 5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; SCC15, squamous cell carcinoma-15 cells.

(A)

(B)

Figure
8 Inhibition of ?-T-FU-PLGA-NPs and 5-FU-PLGA-NPs on
drug-resistant SCC15 cells detected by MTT assay.

Notes:
(A) Dose-concentration dependent
inhibition rate (B) Time-dependent inhibition rate.

Abbreviations:
?-T-FU-PLGA-NPs, targeted ?-Tocopherol-5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; 5-FU-PLGA-NPs, non-targeted 5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; SCC15, squamous cell carcinoma-15 cells; MTT, methyl thiazolyl
tetrazolium assay.

Figure
9 Cell viability assays of ?-T-FU-PLGA-NPs and
5-FU-PLGA-NPs in SCC-15 at the concentration of 1.0mg/ml, .05mg/ml &
0.1mg/ml.

Abbreviations:
?-T-FU-PLGA-NPs, targeted ?-tocopherol-5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; 5-FU-PLGA-NPs, non-targeted 5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; SCC15, squamous cell carcinoma-15 cells.

Figure:
10- Cellular Uptake of FITC labeled ?-T-FU-PLGA-NPs and 5-FU-PLGA-NPs

Notes
(A) ?-T-FU-PLGA-NPs
(B) 5-FU-PLGA NPs in SCC15 by
Fluorescent Microscopy analysis on the scale bar is 50 ?m

Abbreviations:
?-T-FU-PLGA-NPs, targeted ?-tocopherol-5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; 5-FU-PLGA-NPs, non-targeted 5-Fluorouracil-poly(D,L-lactic-co-glycolic)
nanoparticles; SCC15, squamous cell carcinoma-15 cells; FITC, Fluorescein
Isothiocyanate.